EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte Studie

Preference for Cal/BDP Cream or Foam in Patients With Mild to Moderate Plaque Psoriasis

Leon H Kircik, Zoe Diana Draelos, Brad Glick, Lawrence Green, Cheryl Burgess

Journal of Drugs in Dermatology · 2024

DOI: 10.36849/jdd.7993 ↗

At a glance

Randomisierte kontrollierte Studie in Journal of Drugs in Dermatology, 2024. Written by Leon H Kircik and 4 co-authors. Major MEDLINE topics: Psoriasis, Calcitriol, Betamethasone, Drug Combinations. Cited 2 times so far (Crossref).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

BACKGROUND: The combined use of topical calcipotriol/betamethasone dipropionate (Cal/BDP) is commonly used and demonstrated to be effective for the management of psoriasis and is shown to confer local anti-inflammatory and immunoregulatory effects. The use of the two agents in combination is synergistic. Despite the demonstrated efficacy of topically applied combination Cal/BDP, successful management of a chronic, relapsing inflammatory skin disease such as psoriasis in the real-world setting may be hindered if patients do not adhere to the dosing or frequency of application recommendations from their prescriber. Patient preference for and satisfaction with the topical treatment vehicle have been shown to influence adherence. A recent analysis has determined that patients perceived Cal/BDP cream vehicle with PAD technology as having favorable characteristics. This randomized, split-body study was undertaken to further assess patient satisfaction with Cal/BDP cream and Cal/BDP foam formulations. TRIAL DESIGN: This was a split-body, subject-blind study. Study cream was administered in a single application to one side of the scalp and/or body; study foam was applied to the contralateral side. Patient self-administered questionnaires were completed before and after product application after a single site visit. RESULTS: Mean overall Vehicle Preference Measure (VPM) scores were higher for Cal/BDP cream than Cal/BDP foam (P=0.0043). Cal/BDP cream also achieved higher individual scores for ease of application, feeling to the touch, smell, and feeling on the skin (P

Subjects

MeSH terms (MEDLINE)

PsoriasisCalcitriolBetamethasoneDrug CombinationsPatient PreferenceDermatologic AgentsSkin CreamHumansFemaleMaleMiddle AgedAdultAdministration, CutaneousSingle-Blind MethodSeverity of Illness IndexAgedTreatment OutcomePatient SatisfactionSurveys and Questionnaires

Substances

CalcitriolBetamethasoneDrug Combinationsbetamethasone-17,21-dipropionateDermatologic Agentscalcipotriene

Cite

APA

Kircik, L. H., Draelos, Z. D., Glick, B., Green, L., & Burgess, C. (2024). Preference for Cal/BDP Cream or Foam in Patients With Mild to Moderate Plaque Psoriasis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7993

Vancouver

Kircik LH, Draelos ZD, Glick B, Green L, Burgess C. Preference for Cal/BDP Cream or Foam in Patients With Mild to Moderate Plaque Psoriasis. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.7993

BibTeX
@article{Kircik2024,
  author = {Kircik, Leon H and Draelos, Zoe Diana and Glick, Brad and Green, Lawrence and Burgess, Cheryl},
  title = {Preference for Cal/BDP Cream or Foam in Patients With Mild to Moderate Plaque Psoriasis},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  doi = {10.36849/jdd.7993}
}
Start for free →